Connect to share and comment

Kolon wins in appeals court over DuPont in U.S. lawsuit

WASHINGTON, April 3 (Yonhap) -- A U.S. appeals court on Thursday overturned a 2012 verdict against Kolon Industries Inc. of South Korea that awarded DuPont Co. $919.9 million in damages. DuPont, the largest U.S. chemical firm by market value, has alleged its South Korean rival stole some trade secrets for Kevlar, a fiber used to make tires, fiber-optic cables and bullet-proof vests. In 2012, jurors in a federal court in Richmond, Va., delivered a verdict in favor of DuPont, ordering Kolon to pay $919.9 million.

Kolon wins in appeals court over DuPont in U.S. lawsuit

WASHINGTON, April 3 (Yonhap) -- A U.S. appeals court on Thursday overturned a 2012 verdict against Kolon Industries Inc. of South Korea that awarded DuPont Co. $919.9 million in damages. DuPont, the largest U.S. chemical firm by market value, has alleged its South Korean rival stole some trade secrets for Kevlar, a fiber used to make tires, fiber-optic cables and bullet-proof vests. In 2012, jurors in a federal court in Richmond, Va., delivered a verdict in favor of DuPont, ordering Kolon to pay $919.9 million.

UN climate chief urges radical clean-up of oil, gas industry

By Alister Doyle, Environment Correspondent OSLO (Reuters) - The U.N.'s climate chief called on the oil and gas industry on Thursday to make a drastic shift to a clean, low-carbon future or risk having to leave three-quarters of fossil fuel reserves in the ground. "The time for experimentation, for marginal changes and for conditional response is now over," Christiana Figueres told the International Petroleum Industry Environmental Conservation Association (IPIECA) in a speech in London.

Drugmaker Novartis files patent suit against Biocon over Galvus

ZURICH (Reuters) - Novartis has taken India's Biocon to court for infringing the patent on its diabetes drug Galvus, the Swiss drugmaker said in a statement on Thursday. The Basel-based firm has filed infringement proceedings and is seeking an injunction against Biocon at Delhi's High Court to try to stop the Indian company launching a generic version of Galvus, also known as vildagliptin.

Drugmaker Novartis files patent suit against Biocon over Galvus

ZURICH (Reuters) - Novartis has taken India's Biocon to court for infringing the patent on its diabetes drug Galvus, the Swiss drugmaker said in a statement on Thursday. The Basel-based firm has filed infringement proceedings and is seeking an injunction against Biocon at Delhi's High Court to try to stop the Indian company launching a generic version of Galvus, also known as vildagliptin.

Nigella Lawson 'barred from US' after cocaine admission

Celebrity British chef Nigella Lawson has reportedly been barred from entering the United States following her courtroom admission that she had taken cocaine, raising questions Thursday over her successful TV career stateside. The 54-year-old said last year she had taken cocaine occasionally in the past but was not addicted, as she gave evidence in the trial of two former personal assistants who were later cleared of fraud. British police reviewed Lawson's evidence but announced they would not be bringing any charges against the so-called "Domestic Goddess".

Novartis replaces top management in Japan after probe on clinical trials

TOKYO (Reuters) - Novartis AG replaced the top managers at its Japanese unit on Thursday after a third-party probe found employees had acted questionably in clinical trials on a leukaemia treatment. The probe's findings included possible destruction of evidence and the potential obtaining of patients' personal data by employees of the Japanese unit, Novartis Pharma K.K. said in a statement.

Novartis' top Japan executives quit over cancer drug scandal

Swiss pharmaceutical giant Novartis said Thursday it was replacing the top executives at its Japanese unit over allegations the division hid serious potential side effects of leukaemia treatments from regulators. The company also said it was freezing funding for clinical trials in the country in the wake of the scandal, which David Epstein, head of the firm's pharmaceutical division, branded "unacceptable and a clear violation of our code of conduct". Epstein told a press briefing in Tokyo that the senior managers "resigned, they are out of the company".

Novartis' top Japan executives quit over cancer drug scandal

Swiss pharmaceutical giant Novartis said Thursday it was replacing the top executives at its Japanese unit over allegations the division hid serious potential side effects of leukaemia treatments from regulators. The company also said it was freezing funding for clinical trials in the country in the wake of the scandal, which David Epstein, head of the firm's pharmaceutical division, branded "unacceptable and a clear violation of our code of conduct". Epstein told a press briefing in Tokyo that the senior managers "resigned, they are out of the company".

Novartis' top Japan executives quit over cancer drug scandal

Swiss pharmaceutical giant Novartis said Thursday it was replacing the top executives at its Japanese unit over allegations the division hid serious potential side effects of leukaemia treatments from regulators. David Epstein, the head of the firm's pharmaceutical division, said the senior managers "resigned, they are out of the company", adding that "this kind of behaviour is unacceptable and a clear violation of our code of conduct". "I'd like to once again apologise for Novartis' involvement in this issue," Epstein told a press briefing in Tokyo.
Syndicate content